Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
EPS (Diluted)
Innovent Biologics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innovent Biologics Inc
HKEX:1801
|
EPS (Diluted)
¥0
|
CAGR 3-Years
68%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
EPS (Diluted)
-¥4
|
CAGR 3-Years
17%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
EPS (Diluted)
¥0
|
CAGR 3-Years
23%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
EPS (Diluted)
¥6
|
CAGR 3-Years
27%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
EPS (Diluted)
-¥1
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
Glance View
In the bustling landscape of the biotechnology industry, Innovent Biologics Inc. stands out as a dynamic player committed to advancing precision medicine. Founded in 2011, this Chinese-based company has carved out a significant niche in the development of monoclonal antibodies for oncology, metabolic disorders, and autoimmune diseases. Innovent sought to bridge the gap between innovation and affordability, an ambitious vision fueled by strategic collaborations with global pharma giants and local research centers. The company’s flagship product, Tyvyt (sintilimab), is a testament to their pioneering spirit—a PD-1 inhibitor developed in partnership with Eli Lilly, which gained approval for the treatment of various cancers in China. Innovent leverages its robust in-house R&D capabilities and partnerships to craft an extensive pipeline of potential therapies, positioning itself as a linchpin in the race to address unmet medical needs across its target markets. Innovent Biologics generates revenue through strategic licensing agreements, collaborative development programs, and direct sales of its commercialized therapies. It adopts a multinational partnership model that allows it to both share development costs and tap into broader distribution channels, thus accelerating growth while minimizing financial risk. By focusing on biopharmaceuticals that address prevalent health concerns, Innovent capitalizes on the rising demand for innovative healthcare solutions in China and beyond. Furthermore, the company's vertically integrated infrastructure—from research to commercialization—ensures optimized costs and sustained profitability in a competitive industry landscape. Innovent’s financial trajectory is buoyed by its ability to balance cutting-edge scientific innovation with strategic market positioning, underscoring its reputation as a formidable force in global biotech.
See Also
What is Innovent Biologics Inc's EPS (Diluted)?
EPS (Diluted)
-0.1
CNY
Based on the financial report for Dec 31, 2024, Innovent Biologics Inc's EPS (Diluted) amounts to -0.1 CNY.
What is Innovent Biologics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
47%
Over the last year, the EPS (Diluted) growth was 91%. The average annual EPS (Diluted) growth rates for Innovent Biologics Inc have been 68% over the past three years , 47% over the past five years .
You don't have any saved screeners yet